Prostate cancer costs in Colombia: a top-down approach

Objectives To describe the costs and epidemiology of adult patients with castration-resistant prostate cancer with bone metastases and no known visceral metastatic disease in Colombia. Methods We carried out a cost description study using the top-down technique, from the perspective of the third payer-health service provider. We used billing and payment authorization databases of two health insurance companies, one from the subsidiary regime (SRIC) and other from the contributory one (CRIC). Both insurance companies with two million affiliates each, 48% men. Clinical records were refined using the codes C61X and D400 from ICD-10. All costs were calculated for patients treated in 2016 and inflated to 2017 Colombian pesos. Means and 95% confidence intervals were used to report the costs, considering the following cost categories: medication, outpatient physician services, non-physician health services, and inpatient treatment. Results According to the Colombian National Cancer Institute, between 2007-2011, the age-adjusted incidence of prostate cancer (PTC) in Colombia was 46.5 cases per 100,000 (8,872 cases). In the SRIC were observed 595 patients with PTC, similar to the prevalence of this type of cancer reported for Colombia, while in the CRIC we observed 1,779 cases. The average annual direct medical cost of a patient without prostatectomy was $5,594,079 for SRIC and $7,015,942 for CRIC, while with prostatectomy this direct cost was $13,486,265 and $6,660,353, respectively. The average annual direct medical cost of patients with chemical castration using Bicalutamide was $6,844,370 for SRIC and $9,293,649 for CRIC. Also, castration direct medical cost with Goserelin was $9,552,550 and $9,116,249 for SRIC and CRIC, respectively. Conclusions PTC remains as an important public health issue with a high economic burden. Drugs comprised the largest share of cost per item in these patients with 53% and 38.2% for the SRIC and CRIC, respectively. Our estimations are important inputs to estimate cost-effectiveness ratios of PTC drugs.

• Autores: Gomez de la Rosa, F; Carrasquilla-Sotomayor, M; Alvis-Zakzuk, NJ; Acero Acero, G; Alfonso Quiñones, PA; Romero Prada, ME; Alvis-Guzmán, N
• Tipo de recurso: Article of journal
• Fecha de publicación: 2018
• Institución: Corporación Universidad de la Costa
• Repositorio: REDICUC - Repositorio CUC
• Idioma: eng
• OAI Identifier: oai:repositorio.cuc.edu.co:11323/4716
• Acceso en línea: https://hdl.handle.net/11323/4716; https://repositorio.cuc.edu.co/
• Palabra clave: Castración con metástasis óseas; Colombia; The costs and epidemiology of adult patients with prostate cancer; Castration with bony metastases; Colombia; Los costos y la epidemiología de pacientes adultos con cáncer de próstata
• Rights: openAccess
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/